AXGN:NASDAQ
AxoGen, Inc Common Stock
US$37.46
arrow_downward
-1.47%(-0.56) 1 天
US$36.96
arrow_downward
-1.34% (-0.50)bedtime盘后交易
休市： 10月27日, GMT-4 16:00:01 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 AXGN 生成关键数据洞见…
开盘价
US$38.14
最高价
US$39.04
最低价
US$37.23
市值
21.94亿
平均成交量
137.39万
成交量
245.78万
52 周最高价
US$52.91
52 周最低价
US$17.14
每股收益
-US$0.68
Beta 版
1.17
流通股数
5867.20万
员工人数
622
开盘价
US$38.14
最高价
US$39.04
最低价
US$37.23
市值
21.94亿
平均成交量
137.39万
成交量
245.78万
52 周最高价
US$52.91
52 周最低价
US$17.14
每股收益
-US$0.68
Beta 版
1.17
流通股数
5867.20万
员工人数
622
新闻报道
来自网络来源和新闻合作伙伴
Investing.com
·
8小时前
Axogen earnings up next: Can nerve repair leader return to profit?
资料
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
AxoGen, Inc Common Stock简介